84 related articles for article (PubMed ID: 9065279)
1. [Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy].
López López C; Quilez Fenoll JM; Gómez Ruiz JJ; López López AF; Romero Maroto YJ
Arch Esp Urol; 1996 Oct; 49(8):819-23. PubMed ID: 9065279
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
3. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
4. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
5. [The role of neoadjuvant treatment prior to radical prostatectomy].
Sassine AM; Schulman C
Acta Urol Belg; 1992; 60(3):61-71. PubMed ID: 1492635
[TBL] [Abstract][Full Text] [Related]
6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
8. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
[TBL] [Abstract][Full Text] [Related]
10. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
11. Total cystoprostatectomy in the treatment of locally advanced prostate carcinoma.
Sato K; Tsuchiya N; Habuchi T; Satoh S; Shimoda N; Kato T
Aktuelle Urol; 2003 Jul; 34(4):259-61. PubMed ID: 14566679
[TBL] [Abstract][Full Text] [Related]
12. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
13. [Total androgen blockade for prostate cancer].
Kagebayashi Y; Ozono S; Takashima K; Yoshikawa M; Hayashi Y; Kaneko Y; Maruyama Y; Hirao Y; Okajima E
Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
[TBL] [Abstract][Full Text] [Related]
14. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Amling CL; Blute ML; Bergstralh EJ; Slezak JM; Martin SK; Zincke H
Semin Urol Oncol; 1997 Nov; 15(4):222-9. PubMed ID: 9421449
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
17. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
18. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
20. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
